Brief: Candel Therapeutics Announces New Data From Ongoing Phase 1 Clinical Trial Of CAN-3110

Candel Therapeutics

19/05/2023 14:46

May 19 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS ANNOUNCES NEW DATA FROM ONGOING PHASE
1
CLINICAL TRIAL OF CAN-3110 IN RECURRENT HIGH-GRADE GLIOMA AT THE
AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) 26TH ANNUAL
MEETING
    * CANDEL THERAPEUTICS INC - CAN-3110 WAS REPORTED TO BE WELL
TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED
    * CANDEL THERAPEUTICS - TREATMENT WITH CAN-3110 IN ARM A
SHOWED
ENCOURAGING MEDIAN OVERALL SURVIVAL RATE AT 11.8 MONTHS AFTER A
SINGLE INJECTION

Source text for Eikon:  ID:nGNX7vnsKZ 
Further company coverage:  CADL.O 

 ((Reuters.Brief@thomsonreuters.com;))